Predicting Preeclampsia in Gestational Diabetes Mellitus Using the sFlt-1/PlGF Ratio
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgaf069 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Sarah Brittany Noonan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Melbourne Medical School, The University of Melbourne, Melbourne 3052, Australia. Hauptthemen laut MEDLINE: Diabetes, Gestational, Vascular Endothelial Growth Factor Receptor-1, Pre-Eclampsia, Placenta Growth Factor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
The soluble Fms-like tyrosine kinase-1/placental growth factor (sFlt-1/PlGF) ratio blood test can aid the prediction of preeclampsia (PE) in advance of a clinical diagnosis. Gestational diabetes mellitus (GDM) predisposes to PE, but may influence levels of these biomarkers independently of PE.
Objective
To determine whether the sFlt-1/PlGF ratio retains its clinical utility to predict PE in patients with GDM.
Methods
Retrospective analysis of sFlt-1/PlGF ratio and associated clinical outcome data acquired between September 2016 and September 2022, at the Royal Women's Hospital, Melbourne, Australia. 1416 sFlt-1/PlGF ratio results from pregnant women with and without GDM, and with and without PE were analysed. The main outcome measures were sFlt-1, PlGF and sFlt-1/PlGF ratio test results in relation to PE and GDM.
Results
There were no significant differences in the area under the curve (AUC), specificity, sensitivity, positive predictive value, or negative predictive value (NPV) between the PE + No GDM and PE + GDM groups in both the 0 to 7 and the 8 to 14 days before delivery categories. In the 0- to 7-day category the PE + No GDM group had an AUC of 0.82 (95% CI 0.79-0.87), sensitivity of 85.3% (95% CI 80.8-89.1%) and NPV of 92.7% (95% CI 90.5-94.5%), and the PE + GDM group had an AUC of 0.87 (95% CI 0.82-0.93), sensitivity of 89.4% (95% CI 76.9-96.5%), and NPV of 94.8% (95% CI 88.7-97.7%).
Conclusion
The results of this investigation indicate that although GDM may lead to changes in the sFlt-1/PlGF ratio, the sFlt-1/PlGF ratio test retains its clinical utility in predicting PE onset.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Melbourne Medical School, The University of Melbourne, Melbourne 3052, Australia.
- Pregnancy Research Centre, Department of Maternal-Fetal Medicine, Royal Women's Hospital, Parkville 3052, Australia.
- Department of Obstetrics, Gynaecology and Newborn Health University of Melbourne, Parkville, VIC 3052, Australia.
- Oxford Digital Health Labs, Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford OX3 9DU, UK.
ORCID-Profile: Sarah Brittany Noonan, Shaun Patrick Brennecke, Gabriel Davis Jones
Zitieren
APA
Noonan, S. B., Brennecke, S. P., & Jones, G. D. (2025). Predicting Preeclampsia in Gestational Diabetes Mellitus Using the sFlt-1/PlGF Ratio. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf069
Vancouver
Noonan SB, Brennecke SP, Jones GD. Predicting Preeclampsia in Gestational Diabetes Mellitus Using the sFlt-1/PlGF Ratio. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf069
BibTeX
@article{Noonan2025,
author = {Noonan, Sarah Brittany and Brennecke, Shaun Patrick and Jones, Gabriel Davis},
title = {Predicting Preeclampsia in Gestational Diabetes Mellitus Using the sFlt-1/PlGF Ratio},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgaf069}
}
EUVIMED